Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/01/2005US20050191275 Method for short-term and long-term drug dosimetry
09/01/2005US20050191274 Contacting peripheral blood mononuclear cell population with an amount of rhesus or human CMV interleukin IL-10 to inhibit proliferation; antiinflammatory, antiallergen, and bronchodilator agents; rheumantic, skin, gastrointestinal, autoimmune, Grave*s, and Hashimoto*s diseases; multiple sclerosis,
09/01/2005US20050191273 Cytokine inhibition of eosinophils
09/01/2005US20050191248 such as silk or bleomycin; treatment for a dental condition such as periodontal disease
09/01/2005US20050191246 Powders comprising low molecular dextran and methods of producing those powders
09/01/2005US20050191241 Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
09/01/2005US20050191240 Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes
09/01/2005US20050188702 Non-catalytic combustor for reducing nox emissions
09/01/2005DE102004038076A1 Use of annexin A3, or other proteins, as diagnostic markers for cancer, especially of the prostate, also use of modulators of these markers for treating cancer
09/01/2005CA2558770A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions
09/01/2005CA2557725A1 Highly active glycoproteins-process conditions and an efficient method for their production
09/01/2005CA2557669A1 Cysteine protease from ginger (zingiber) as a food improver and anti-inflammatory
09/01/2005CA2557631A1 Propenoyl hydrazides
09/01/2005CA2557595A1 Vectors having both isoforms of beta-hexosaminidase and uses of the same
09/01/2005CA2557540A1 A cancer combination therapy comprising an antitumor agent and an hdac inhibitor
09/01/2005CA2557333A1 Antifungal peptides
09/01/2005CA2557154A1 Anticancer agent containing bl-angiostatin
09/01/2005CA2556805A1 Use of factor xiii for stimulating the perfusion of ischemic tissue
09/01/2005CA2556803A1 T cell immune response inhibitor
09/01/2005CA2556690A1 New complexes
09/01/2005CA2556425A1 Methods of modulating il-23 activity; related reagents
09/01/2005CA2556098A1 Wound healing composition
09/01/2005CA2555984A1 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
09/01/2005CA2555939A1 Treatment of abnormalities of the first metatarsophalangeal joint of the foot
09/01/2005CA2555841A1 Interleukin-13 antagonist powders, spray-dried particles, and methods
09/01/2005CA2555826A1 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
09/01/2005CA2555772A1 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
09/01/2005CA2555737A1 Schizochytrium fatty acid synthase (fas) and products and methods related thereto
09/01/2005CA2555421A1 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders
09/01/2005CA2555417A1 Inhibition of fgf signaling
09/01/2005CA2555236A1 Methods of modulating cytokine activity; related reagents
09/01/2005CA2555233A1 Wound healing profile
09/01/2005CA2554537A1 Method and composition for angiogenesis inhibition
09/01/2005CA2553369A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2552939A1 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins
09/01/2005CA2552903A1 Pharmaceutical compositions based on anticholinergics and pegsunercept
09/01/2005CA2498682A1 System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor
08/2005
08/31/2005EP1568779A1 HSV strains for the oncolytic treatment of cancer
08/31/2005EP1568775A1 Cancer-associated gene
08/31/2005EP1568772A2 Human growth hormone variants
08/31/2005EP1568771A2 Human growth hormone variants
08/31/2005EP1568770A2 Pharmaceutical use of compounds which bind to a mammalian "trace amine" receptor
08/31/2005EP1568769A1 ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR
08/31/2005EP1568709A2 Purification of fibrinogen
08/31/2005EP1568708A2 Methods and medical uses of nucleic acids encoding a TRAF inhibitor
08/31/2005EP1568707A1 Antihypertensive peptides from casein hydrolysates
08/31/2005EP1568377A1 Cysteine protease inhibitor
08/31/2005EP1568376A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
08/31/2005EP1568375A1 Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
08/31/2005EP1568374A1 Use of DMBT1 for capturing sulphate and phosphate group exposing agents
08/31/2005EP1568373A2 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
08/31/2005EP1567868A2 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
08/31/2005EP1567864A2 Composition for treating chlamydia infections and method for identifying same
08/31/2005EP1567663A2 Molecular determinants of myeloma bone disease and uses thereof
08/31/2005EP1567651A2 Production of pharmaceutically active proteins in sprouted seedlings
08/31/2005EP1567645A1 Inhibitors of gst a3-3 and gst a1-1 for the treatment of cancer
08/31/2005EP1567644A2 Tissue specific genes and gene clusters
08/31/2005EP1567642A2 Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
08/31/2005EP1567641A2 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
08/31/2005EP1567640A2 Pokeweed antiviral protein polypeptides with antiviral activity
08/31/2005EP1567552A2 Novel ifngamma-like polypeptides
08/31/2005EP1567551A2 Colostrinin and peptides thereof as modulators of intracellular signaling molecules and inhibitors of apoptosis
08/31/2005EP1567546A2 Aza-peptides
08/31/2005EP1567545A2 Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
08/31/2005EP1567542A2 Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians
08/31/2005EP1567539A2 Allele-specific rna interference
08/31/2005EP1567538A2 Antisense modulation of gfat expression
08/31/2005EP1567202A1 Wound dressings containing an enzyme therapeutic agent
08/31/2005EP1567199A2 Neuroprotective activity of activated protein c is independent of its anticoagulant activity
08/31/2005EP1567198A2 Materials and methods for treating ocular-related disorders
08/31/2005EP1567196A2 Modulation of notch3 expression
08/31/2005EP1567190A2 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
08/31/2005EP1567187A1 Proteins involved in the regulation of energy homeostasis
08/31/2005EP1567186A2 Nogo, caspr, f3 and nb-3 useful in the treatment of injury and disease to the central nervous system
08/31/2005EP1567185A2 Broad spectrum anti-viral therapeutics and prophylaxis
08/31/2005EP1567183A2 Methods and compositions for treatment of otitis media
08/31/2005EP1567182A2 Preventing desensitization of receptors
08/31/2005EP1567181A2 Methods for treatment of helicobacter pylori-associated disorders
08/31/2005EP1567180A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism
08/31/2005EP1567179A1 Irrigation solution and method for inhibition of tumor cell adhesion, pain and inflammation
08/31/2005EP1567178A1 Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
08/31/2005EP1567172A2 Formulations useful against hepatitis c virus infections
08/31/2005EP1567169A2 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
08/31/2005EP1567160A2 Method of treatment of myocardial infarction
08/31/2005EP1567148A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
08/31/2005EP1567144A2 Method of making, and the use of cytotoxic agents containing elemental selenium
08/31/2005EP1567129A1 Artificial blood on the basis of encapsulated haemoglobin
08/31/2005EP1567127A2 Method of modifying the release profile of sustained release compositions
08/31/2005EP1567102A2 Soluble oral patch with collagen and interlaced active ingredients
08/31/2005EP1567022A1 Sustained improver of muscular fatigue
08/31/2005EP1461063A4 Treatment of glioblastoma with thymosin-alpha 1
08/31/2005EP1448246B1 Homogeneously coated device having osteoinductive and osteoconductive properties
08/31/2005EP1392288B1 Medicament containing an effector of the glutathione metabolism (ampbroxol) together with alpha-lipoic acid for treating diabetes mellitus
08/31/2005EP1330257B1 Gnrh analogues for treatment of urinary incontinence
08/31/2005EP1267881B1 USE OF MnTBAP FOR TREATING HEPATOCELLULAR INSUFFICIENCIES
08/31/2005EP1254247B1 Protein and oat beta glucan hydrolysate for use in cosmetology and method for making same
08/31/2005EP1173475B1 Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients
08/31/2005EP1117424B1 Null igf for the treatment of cancer
08/31/2005EP1095020B1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them
08/31/2005EP0973819B1 Non-antigenic branched polymer conjugates
1 ... 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 ... 3163